{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:00:29Z","timestamp":1758474029062,"version":"3.41.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Corticobasal syndrome (CBS) is characterized by a slow progressive cognitive decline, apraxia, myoclonus, dystonia, and parkinsonism. We experienced a rapidly progressing CBS patient (onset to bed-ridden within 2 years) presenting only with resting tremor but showing complete unilateral loss of dopamine transporter binding. This case exhibited distinct FDG PET findings involving the unilateral severe anterior frontal cortex, caudate nucleus, and contralateral cerebellum, which is different from classical CBS. However, to date, no detailed serial functional imaging study has been performed in rapidly progressing CBS, so these FDG PET and CIT PET findings may help clinicians to recognize this fulminant type of corticobasal degeneration.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003679","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T03:01:55Z","timestamp":1620010915000},"page":"754-755","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Serial 18F-FP-CIT and FDG PET in Fulminant Corticobasal Syndrome"],"prefix":"10.1097","volume":"46","author":[{"given":"Don Gueu","family":"Park","sequence":"first","affiliation":[{"name":"Neurology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Sil","family":"An","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Ajou University School of Medicine, Suwon, South Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Han","family":"Yoon","sequence":"additional","affiliation":[{"name":"Neurology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","year":"2013","journal-title":"Neurology"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00401-019-02119-4","article-title":"Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates","volume":"139","year":"2020","journal-title":"Acta Neuropathol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1212\/WNL.0000000000002491","article-title":"Fulminant corticobasal degeneration: agrypnia excitata in corticobasal syndrome","volume":"86","year":"2016","journal-title":"Neurology"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3233\/JPD-150625","article-title":"Progressive dopamine transporter binding loss in autopsy-confirmed corticobasal degeneration","volume":"5","year":"2015","journal-title":"J Parkinsons Dis"},{"key":"bib5-20250621","first-page":"e1121","article-title":"FDG-PET patterns associated with underlying pathology in corticobasal syndrome","volume":"92","year":"2019","journal-title":"Neurology"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/RLU.0000000000002355","article-title":"Dual-phase 18F-FP-CIT PET in corticobasal syndrome","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1093\/brain\/awr234","article-title":"Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome","volume":"134","year":"2011","journal-title":"Brain"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/RLU.0000000000002949","article-title":"Tau imaging in the 4-repeat-tauopathies progressive supranuclear palsy and corticobasal syndrome: a 11C-pyridinyl-butadienyl-benzothiazole 3 PET pilot study","volume":"45","year":"2020","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:03:54Z","timestamp":1750536234000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003679","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2021,5,3]]}}}